Two cases of chronic graft-versus-host disease with elevated levels of soluble Fas ligand in serum

American Journal of Hematology

Volumn 64, Issue 2, 2000, Pages 133-136

  Takada, Satoru ^a   Hatsumi, Nahoko ^b   Saito, Takayuki ^b   Matsushima, Takahumi ^b   Sakura, Toru ^a   Tamura, Junich ^b   Karasawa, Masamitu ^c   Miyawaki, Shuichi ^a  

^a SAISEIKAI MAEBASHI HOSPITAL   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c GUNMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Chronic GVHD; Liver dysfunction; Soluble Fas ligand

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FAS LIGAND; LIVER ENZYME; METHOTREXATE; PREDNISOLONE; STEROID;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD LEVEL; CASE REPORT; CHRONIC DISEASE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER DYSFUNCTION; MALE; PATHOGENESIS; PRIORITY JOURNAL; STEROID THERAPY;

ADOLESCENT; CHRONIC DISEASE; CYCLOSPORINE; FAS LIGAND PROTEIN; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PREDNISOLONE; SOLUBILITY;

EID: 0034074477     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(200006)64:2<133::AID-AJH12>3.0.CO;2-Z     Document Type: Article

References (12)

1. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324:667-674.
2. Nagata S, Golstein P. The Fas Death Factor. Science 1995;267:1449-1456
3. Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nat Med 1996;2:317-322.
4. Sato K, Kimura F, Nakamura Y, et al. An aggressive nasal lymphoma accompanied by high levels of soluble Fas Ligand. Br J Haematol 1996;94:379-382.
5. Kanda Y, Tanaka Y, Shirakawa K, et al. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplant 1998;22:751-754.
6. Kayagaki N, Yagita H. Metalloproteinase-mediated release of human Fas ligand. Nippon Rinsho 1996;54:1747-1752.
7. Mohler KM, Sleath PR, Fitzner, JN, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing. Nature 1994;370:218-220.
8. Tanaka M, Suda T. Takahashi T, et al. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995;14:1129-1135.
9. Tanaka M, Suda T, Yatomi T, et al. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J Immunol 1997;158:2303-2309.
10. Schneider P, Holler N, Bodmer JL, et al. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with down-regulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998;187:1205-1213.
11. Via CS, Nguyen P, Shustov A, et al. A major role for the Fas pathway in acute graft-versus-host disease. J Immunol 1996;157:5387-5393.
12. Hattori K, Hirano T, Miyajima H, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor α antibodies on acute graft-versus-host disease pathologies. Blood 1998;91:4051-4055.